drugset / Trial / NCT05914688
A Study to Compare Two Formulations of LY3209590 in Healthy Participants
RandomizedCrossoverDouble-blindBasic science
Summary
The main purpose of this study is to compare the two formulations of LY3209590 in healthy participants. Study participants will be administered each formulation at separate study visits. Blood samples will be taken to compare how the body handles study drugs. The information about any adverse effects experienced will be collected and the tolerability of LY3209590 will also be evaluated. Screening is required within 28 days prior to enrolment. For each participant, the total duration of the clinical trial will be about 184 days including screening.
Timeline
- Start
- 2023-06-26
- Primary completion
- 2024-01-18
- Completion
- 2024-01-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin Efsitora Alfa | Protein / enzyme biologic | — | Subcutaneous |
Indications
No indication recorded.